Astellas Announces Update on Preliminary Safety and Efficacy Data from FORTIS Study of Investigational AT845 in Adults with Late-Onset Pompe Disease ...Middle East

Data presented at the 19th Annual WORLDSymposium™ 2023 TOKYO, Feb. 22, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced an update on preliminary safety and efficacy data from its ongoing FORTIS Phase1/2 clinical...

Hence then, the article about astellas announces update on preliminary safety and efficacy data from fortis study of investigational at845 in adults with late onset pompe disease was published today ( Wednesday 22/02/2023 - 11:08 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Astellas Announces Update on Preliminary Safety and Efficacy Data from FORTIS Study of Investigational AT845 in Adults with Late-Onset Pompe Disease )

Also on site :

• Serena Williams models swimsuit with slippers after weight loss medication backlash: ‘I’m perfectly me’
• Live Nation Antitrust Trial to Resume Monday as Company Fails to Reach Settlement With States
• Jorge Drexler Breaks Down 5 Essential Tracks From ‘Taracá’: ‘An Album of Mourning With a Clear Celebratory Nature’